Healthcare of Ontario Pension Plan Trust Fund Has $17.05 Million Stock Holdings in Axonics, Inc. (NASDAQ:AXNX)

Healthcare of Ontario Pension Plan Trust Fund lifted its holdings in shares of Axonics, Inc. (NASDAQ:AXNX) by 9.2% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 245,000 shares of the company’s stock after buying an additional 20,700 shares during the period. Healthcare of Ontario Pension Plan Trust Fund owned about 0.48% of Axonics worth $17,052,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Absolute Gestao de Investimentos Ltda. bought a new stake in shares of Axonics in the 2nd quarter valued at about $32,681,000. Alpine Associates Management Inc. raised its holdings in shares of Axonics by 16.2% in the 2nd quarter. Alpine Associates Management Inc. now owns 2,108,871 shares of the company’s stock valued at $141,779,000 after purchasing an additional 294,100 shares during the period. Squarepoint Ops LLC raised its holdings in shares of Axonics by 3,961.0% in the 2nd quarter. Squarepoint Ops LLC now owns 190,500 shares of the company’s stock valued at $12,807,000 after purchasing an additional 185,809 shares during the period. P Schoenfeld Asset Management LP raised its holdings in shares of Axonics by 65.6% in the 2nd quarter. P Schoenfeld Asset Management LP now owns 429,075 shares of the company’s stock valued at $28,847,000 after purchasing an additional 170,000 shares during the period. Finally, Janus Henderson Group PLC raised its holdings in shares of Axonics by 637.7% in the 1st quarter. Janus Henderson Group PLC now owns 178,322 shares of the company’s stock valued at $12,298,000 after purchasing an additional 154,149 shares during the period. 99.48% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Axonics

In related news, CFO Kari Leigh Keese sold 2,961 shares of the business’s stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $69.41, for a total value of $205,523.01. Following the completion of the transaction, the chief financial officer now owns 40,362 shares of the company’s stock, valued at $2,801,526.42. The trade was a 6.83 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 1.85% of the company’s stock.

Axonics Stock Performance

NASDAQ AXNX opened at $70.98 on Friday. The company has a market cap of $3.63 billion, a price-to-earnings ratio of -591.45 and a beta of 0.82. Axonics, Inc. has a 1-year low of $55.09 and a 1-year high of $71.05. The company has a 50 day moving average of $70.21 and a 200-day moving average of $68.79.

Analyst Ratings Changes

Separately, Needham & Company LLC reaffirmed a “hold” rating on shares of Axonics in a report on Friday, November 8th. Eight analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $71.00.

About Axonics

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.